Pregled bibliografske jedinice broj: 762322
Cytoreductive surgery and hyperthermic intraperitoneal perioperative chemotherapy: initial results
Cytoreductive surgery and hyperthermic intraperitoneal perioperative chemotherapy: initial results // 1st Central European Congress of Surgery, European Surgery, Volume 40, supplement issue 223 / Riegler, Martin F (ur.).
Beč: Springer, 2008. str. 32-32 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 762322 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Cytoreductive surgery and hyperthermic intraperitoneal perioperative chemotherapy: initial results
Autori
Matošević, Petar ; Majerović, Mate ; Kekez, Tihomir ; Kinda, Emil ; Smuđ, Dubravko ; Jelinčić, Željko ; Augustin, Goran ; Silovski, Hrvoje
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
1st Central European Congress of Surgery, European Surgery, Volume 40, supplement issue 223
/ Riegler, Martin F - Beč : Springer, 2008, 32-32
Skup
1st Central European Congress of Surgery
Mjesto i datum
Prag, Češka Republika, 23.04.2008. - 26.04.2008
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Cytoreductive surgery ; Hyperthermic intraperitoneal perioperative chemotherapy
Sažetak
Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) improves survival in large volume low-grade tumors such as in pseudomyxoma peritonei and survival in carefully selected patients with high-grade cancers such as ovarian and appendiceal adenocarcinoma, gastric and colorectal cancer. Methods. Seven patients underwent CRS and HIPEC in first year, 5 females and 2 males age 43–75 (median 56.4). Four patients had pseudomyxoma peritonei originating from appendiceal mucinous adenocarcinoma, 3 had carcinomatosis peritonei caused by ovarian cancers. Results. Adequate cytoreduction was performed in all patients. Two patients died in early postoperative period (14th and 42nd day). Other five patients are evaluated every three months and are in good clinical condition without evidence of recurrent disease. Conclusions. CRS with HIPEC significantly improves survival of patients with peritoneal carcinomatosis and pseudomyxoma peritonei. However during intorduction period higher morbidity and mortality could expected.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Mate Majerović
(autor)
Petar Matošević
(autor)
Goran Augustin
(autor)
Dubravko Smuđ
(autor)
Hrvoje Silovski
(autor)
Željko Jelinčić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus